Duchenne News Tags: Avidity Biosciences

December 13, 2023

Avidity Biosciences Reports Positive Data Demonstrating AOC 1044 Delivers Unprecedented Concentrations of PMO in Muscle Following a Single Dose in Healthy Volunteers from Phase 1/2 EXPLORE44™ Trial for Duchenne Muscular Dystrophy

Avidity shares an update on positive AOC 1044 data in healthy volunteers from the Phase 1/2 EXPLORE44™ clinical trial.

May 9, 2023

Avidity announces positive topline data from the Phase 1/2 MARINA™ clinical trial of AOC 1001 for the treatment of myotonic dystrophy type 1

April 24, 2023

Avidity announces Fast Track designation to AOC 1044 for the treatment of Duchenne

March 20, 2023

Avidity Biosciences provides an update on the Phase 1/2 MARINA™ trial of AOC 1001 in adults with myotonic dystrophy type 1.

December 14, 2022

Avidity announces positive AOC 1001 date from preliminary MARINA study assessment

Jett Foundation, Inc.
65 Cordage Park Circle
Suite 130 | Plymouth, MA 02360
781-585-5566 | info@jettfoundation.org

Jett Foundation, Inc. is a 501(c)3 registered tax-exempt nonprofit organization. Our Federal Tax ID is 04-3563445.

Sign up to receive our newsletter and updates.
Required fields are denoted with an asterisk (*)

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!